The Beacon H. Jack West, MD

We're removing the West Wind Podcast video feed. You can still watch the podcast in video format on our YouTube channel (/BeaconMedIC) or at the BeaconMedIC.com website. Thanks!

Drs. Hossein Borghaei and host Jack West discuss long term outcomes in lung cancer with immunotherapy, potential utility of IO combinations, and when we can consider patients doing well on immunotherapy as cured if doing well beyond 5 years.

Dr. Hossein Borghaei sits with Dr. Jack West and traces his difficult journey from war-torn Iran to Germary and then the US, which he made alone as a 16 year-old before having the opportunity to pursue medicine & his career in thoracic oncology.

Dr. West questions Dr. Gideon Blumenthal of the FDA about how he and his team there struggle to provide timely access to emerging cancer treatments, while also debating questions of the proper thresholds for efficacy and safety.

Drs. Gideon Blumenthal & Jack West discuss his early career interests and trajectory from medical oncology training at the NIH to joining the Federal Drug Administration (FDA) to regulate oncology drugs.

Dr. Jack West provides a brief summary of key findings & limitations of two new papers just out in JAMA Oncology (Theelen et al & Bauml et al.) that evaluate the potential benefit of preceding immunotherapy with radiation in patients with advanced NSCLC.